Bristol Myers Squibb (CELG-RI) Gross Profit (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Gross Profit for 18 consecutive years, with $9.2 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Gross Profit rose 3.93% year-over-year to $9.2 billion; the TTM figure through Jun 2026 stood at $34.5 billion (up 2.91% YoY), while the FY2025 annual figure was $34.3 billion, changed 0.22% from the prior year.
• Gross Profit climbed to $9.2 billion in Q2 2026 per CELG-RI's latest filing, from $8.1 billion in the prior quarter.
• Across five years, Gross Profit topped out at $9.2 billion in Q2 2026 and bottomed at $7.5 billion in Q4 2024.
• Historically, Gross Profit has averaged $8.7 billion across 5 years, with a median of $8.8 billion in 2022.
• Annual changes were most pronounced in 2024 — Gross Profit fell 13.77% — and 2025, when it rose 11.62%.
• Bristol Myers Squibb's Gross Profit stood at $8.8 billion in 2022, then fell by 0.92% to $8.7 billion in 2023, then dropped by 13.77% to $7.5 billion in 2024, then gained by 11.62% to $8.4 billion in 2025, then grew by 10.02% to $9.2 billion in 2026.
• Business Quant data shows CELG-RI's Gross Profit at $9.2 billion in Q2 2026, $8.1 billion in Q1 2026, and $8.4 billion in Q4 2025.